Entering text into the input field will update the search result below

Inovio's investigational flu vaccine shows broad protection in preclinical studies; shares up 4%

  • Inovio Pharmaceuticals (NASDAQ:INO +4.2%) is up on almost double normal volume on the heels of its announcement of encouraging preclinical data on its universal flu vaccine.
  • In a range of animal models, the vaccine, a collection of synthetic DNA antigens, generated broad protective antibody responses against all major deadly strains of H1 influenza viruses from the past 100 years, including the Spanish Flu bug from 1918. The vaccine protected 100% of immunized ferrets from a lethal virus challenge.
  • The company says the DNA antigens are easy to formulate and can be developed to include seasonal vaccine changes thereby maintaining protection, adding that the immune responses were generated using its skin delivery system.

Recommended For You

About INO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
INO--
Inovio Pharmaceuticals, Inc.